Cell Signaling Technology Logo - Extra Large
Trial Size Available Flag

HECTH9 (AX8D1) Mouse Monoclonal Antibody #5695

Filter:
  • WB

    Product Specifications

    REACTIVITY H M R Mk
    SENSITIVITY Endogenous
    MW (kDa) 482
    Source/Isotype Mouse IgG1
    Application Key:
    • WB-Western Blotting 
    Species Cross-Reactivity Key:
    • H-Human 
    • M-Mouse 
    • R-Rat 
    • Mk-Monkey 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    HECTH9 (AX8D1) Mouse Monoclonal Antibody recognizes endogenous levels of total HECTH9 protein.

    Species Reactivity:

    Human, Mouse, Rat, Monkey

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a recombinant protein specific to human HECTH9 protein.

    Background

    The HECT domain-containing ubiquitin E3 ligase HECTH9 (also known as HUWE1, ARF-BP1, URE-B1, Mule, and LASU1) is critical for the ubiquitination and proteasomal degradation of many target proteins, and is involved in the regulation of a variety of cellular processes, including DNA replication and base excision repair, cellular proliferation, differentiation, and apoptosis. HECTH9 contains two Armadillo (ARM) repeat-like domains (ARLD1 and ARLD2), a ubiquitin-associated (UBA) domain, a WWE domain, a well-conserved BH3 domain, and a catalytic HECT domain that facilitates ubiquitination of target proteins. HECTH9 has been shown to polyubiquitinate p53 (1,2), Miz1 (3), N-Myc (4,5), Mcl-1 (6), Cdc 6 (7), and DNA polymerase beta (8) through K48-mediated linkage, thereby targeting these proteins for proteosomal degradation. The tumor suppressor protein ARF (known as p14 ARF in humans and p19 ARF in mice) binds to and inhibits the uibiquitin ligase activity toward p53, resulting in stabilization of p53 and induction of apoptosis (1). HECTH9 has also been shown to polyubiquitinate c-Myc through K63-linkage, which is required for recruitment of p300, activation of c-Myc target genes, and induction of cellular proliferation (9). HECTH9 is overexpressed in colon, lung, and breast cancer (1,9). In addition, defects in HECTH9 result in mental retardation syndromic X-linked Turner type (MRXST) and mental retardation X-linked type 17 (MRX17) syndromes (10).

    Alternate Names

    ARF binding protein 1; ARF-binding protein 1; ARF-BP1; BJ-HCC-24 tumor antigen; E3 ubiquitin-protein ligase HUWE1; HECT domain protein LASU1; HECT-type E3 ubiquitin transferase HUWE1; HECT, UBA and WWE domain containing 1; HECT, UBA and WWE domain containing 1, E3 ubiquitin protein ligase; HECT, UBA and WWE domain containing E3 ubiquitin protein ligase 1; HECT, UBA and WWE domain-containing protein 1; HectH9; Homologous to E6AP carboxyl terminus homologous protein 9; HSPC272; HUWE1; Ib772; KIAA0312; KIAA1578; Large structure of UREB1; LASU1; Mcl-1 ubiquitin ligase E3; MRXST; Mule; Upstream regulatory element-binding protein 1; URE-B1; URE-binding protein 1; UREB1

    For Research Use Only. Not for Use in Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.